Author

Theresa Hunter Gibble 1

1 El

ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION

David Clemow, Christophe Sapin, Toshifumi Hibi, Marla C. Dubinsky, Severine Vermeire, Stefan Schreiber, Theresa Hunter Gibble, Laurent Peyrin-Biroulet, Mamoru Watanabe, Remo Panaccione

BOWEL URGENCY COMMUNICATION GAP BETWEEN HEALTH CARE PROFESSIONALS AND PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY

Simon Travis, Alison Potts Bleakman, David T. Rubin, Marla C. Dubinsky, Remo Panaccione, Toshifumi Hibi, Theresa Hunter Gibble, Cem Kayhan, Eoin J. Flynn, Christophe Sapin, Christian Atkinson, Stefan Schreiber

BURDEN OF BOWEL URGENCY ACROSS SPECIFIC TREATMENT GROUPS AMONG CROHN’S DISEASE PATIENTS – REAL WORLD GLOBAL STUDY ANALYSES

Raja Atreya, Marijana Protic, Petra Streit, Susanne Hartz, Hannah Knight, Sophie Barlow, Fritha Hennessy, Theresa Hunter Gibble

EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL

Silvio Danese, Axel Dignass, Katsuyoshi Matsuoka, Marc Ferrante, Millie Long, Isabel Redondo, Theresa Hunter Gibble, Richard Moses, Nathan Morris, Xingyuan Li, Catherine Milch, Maria T. Abreu

EFFECT OF MIRIKIZUMAB ON BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT AND REMISSION: RESULTS FROM THE PHASE 3 LUCENT INDUCTION AND MAINTENANCE STUDIES

Simon Travis, Toshifumi Hibi, Tadakazu Hisamatsu, Deborah Fisher, Mingyang Shan, Theresa Hunter Gibble, David T. Rubin

IMPACT OF MIRIKIZUMAB TREATMENT ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CROHN’S DISEASE: A PHASE 2 STUDY ANALYSIS USING THE SF-36

Vipul Jairath, Toshifumi Hibi, Lai Shan Chan, Theresa Hunter Gibble, Hilde Carlier, Xian Zhou, Marijana Protic, David T. Rubin

IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH CLINICAL REMISSION AND PAIN IMPROVEMENTS BUT NOT WITH ENDOSCOPIC RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Miguel Reguiero, Monika Fischer, David T. Rubin, Toshifumi Hibi, Peter Bossuyt, Pascal Juillerat, Paul Pollack, Xian Zhou, Marijana Protic, Theresa Hunter Gibble, Lai Shan Chan, Hilde Carlier, Pieter Hindryckx

IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Miguel Reguiero, Monika Fischer, David T. Rubin, Toshifumi Hibi, Peter Bossuyt, Pascal Juillerat, Paul Pollack, Xian Zhou, Marijana Protic, Theresa Hunter Gibble, Lai Shan Chan, Hilde Carlier, Pieter Hindryckx

MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE SCORES IN PARTICIPANTS OF THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAINTENANCE TRIALS

Bruce E. Sands, Brian G. Feagan, Theresa Hunter Gibble, Kristina Traxler, Nathan Morris, Xingyuan Li, Stefan Schreiber, Vipul Jairath, Alessandro Armuzzi

MIRIKIZUMAB IMPROVES WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE SCORES IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAINTENANCE STUDIES

Bruce E. Sands, Brian G. Feagan, Theresa Hunter Gibble, Kristina Traxler, Nathan Morris, Xingyuan Li, Stefan Schreiber, Vipul Jairath, Alessandro Armuzzi

Item 1 - 10 / 13
1
2